NZ540043A - Isolated or recombinant Interferon-alpha polypeptides and conjugates - Google Patents
Isolated or recombinant Interferon-alpha polypeptides and conjugatesInfo
- Publication number
- NZ540043A NZ540043A NZ540043A NZ54004303A NZ540043A NZ 540043 A NZ540043 A NZ 540043A NZ 540043 A NZ540043 A NZ 540043A NZ 54004303 A NZ54004303 A NZ 54004303A NZ 540043 A NZ540043 A NZ 540043A
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- polypeptide
- amino acid
- sequence
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42761202P | 2002-11-18 | 2002-11-18 | |
| US50256003P | 2003-09-12 | 2003-09-12 | |
| PCT/US2003/036682 WO2004046365A2 (en) | 2002-11-18 | 2003-11-17 | Interferon-alpha polypeptides and conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ540043A true NZ540043A (en) | 2007-11-30 |
Family
ID=32329174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ540043A NZ540043A (en) | 2002-11-18 | 2003-11-17 | Isolated or recombinant Interferon-alpha polypeptides and conjugates |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040219131A1 (enExample) |
| EP (1) | EP1565205A4 (enExample) |
| JP (1) | JP2006506097A (enExample) |
| KR (1) | KR20050086498A (enExample) |
| AU (1) | AU2003297285A1 (enExample) |
| BR (1) | BR0316324A (enExample) |
| CA (1) | CA2504267A1 (enExample) |
| IL (1) | IL168049A0 (enExample) |
| MX (1) | MXPA05005263A (enExample) |
| NO (1) | NO20052363L (enExample) |
| NZ (1) | NZ540043A (enExample) |
| RU (1) | RU2005118998A (enExample) |
| WO (1) | WO2004046365A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002537762A (ja) | 1999-01-05 | 2002-11-12 | トラスティーズ オブ ボストン ユニバーシティ | 改良型核酸クローニング |
| US7435562B2 (en) | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
| US7959910B2 (en) | 2000-07-31 | 2011-06-14 | Biolex Therapeutics, Inc. | C-terminally truncated interferon alpha variants |
| WO2004022593A2 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| RS20050501A (sr) | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora |
| GEP20084486B (en) | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
| CN1997666A (zh) * | 2003-02-26 | 2007-07-11 | 印特缪恩股份有限公司 | 聚乙二醇修饰的干扰素组合物及其使用方法 |
| EP1756173B1 (en) | 2004-01-21 | 2019-04-03 | Nektar Therapeutics | Method of preparing propionic acid-terminated polymers |
| WO2005113592A2 (en) * | 2004-05-19 | 2005-12-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| WO2006004959A2 (en) * | 2004-06-30 | 2006-01-12 | Egen Corporation | Pegylated interferon alpha-1b |
| US20060024272A1 (en) * | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
| ATE540110T1 (de) | 2004-11-11 | 2012-01-15 | Modular Genetics Inc | Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfalt |
| US9931413B2 (en) * | 2005-04-06 | 2018-04-03 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| EP3683230A1 (en) | 2005-05-12 | 2020-07-22 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
| CA2607651A1 (en) | 2005-05-18 | 2007-04-19 | Maxygen, Inc. | Evolved interferon-alpha polypeptides |
| US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
| JP2010504909A (ja) * | 2006-09-14 | 2010-02-18 | メドジェニクス・メディカル・イスラエル・リミテッド | 長期持続性の医薬製剤 |
| CN1970572A (zh) * | 2006-12-21 | 2007-05-30 | 北京三元基因工程有限公司 | 干扰素α突变体及其聚乙二醇衍生物 |
| WO2008124086A2 (en) * | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
| AU2011268458B2 (en) | 2010-06-15 | 2014-06-12 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
| US20130225789A1 (en) * | 2012-02-29 | 2013-08-29 | Yi Sun | Polyethylene Glycol Having Hetero Multiple Functional Groups |
| US20250145680A1 (en) * | 2021-08-18 | 2025-05-08 | Remd Biotherapeutics, Inc. | Novel interferon variants and bifunctional fusion molecules thereof |
| CN117417429A (zh) * | 2022-07-18 | 2024-01-19 | 亚飞（上海）生物医药科技有限公司 | 肿瘤微环境激活的细胞因子及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610830B1 (en) * | 1980-07-01 | 2003-08-26 | Hoffman-La Roche Inc. | Microbial production of mature human leukocyte interferons |
| US4414150A (en) * | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4801685A (en) * | 1981-08-14 | 1989-01-31 | Hoffmann-La Roche Inc. | Microbial production of mature human leukocyte interferon K and L |
| US4678751A (en) * | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| IE54592B1 (en) * | 1982-03-08 | 1989-12-06 | Genentech Inc | Anumal interferons, processes involved in their production, compositions containing them, dna sequences coding therefor and espression vehicles containing such sequences and cells transformed thereby |
| US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| ATE78262T1 (de) * | 1985-06-11 | 1992-08-15 | Ciba Geigy Ag | Hybrid-interferone. |
| US5574138A (en) * | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
| US6335160B1 (en) * | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| KR20020018197A (ko) * | 1999-05-19 | 2002-03-07 | 추후보정 | Ｆｃ 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비 |
| AU8001300A (en) * | 1999-10-07 | 2001-05-10 | Maxygen, Inc. | Ifn-alpha homologues |
| US20020025304A1 (en) * | 2000-06-16 | 2002-02-28 | Croze Edward M. | Novel interferon for the treatment of multiple sclerosis |
| WO2002044197A2 (en) * | 2000-12-01 | 2002-06-06 | Fish Eleanor N | Cytokine receptor binding peptides |
| MXPA05005178A (es) * | 2002-11-15 | 2005-07-22 | Hoffmann La Roche | Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg). |
-
2003
- 2003-11-17 NZ NZ540043A patent/NZ540043A/en unknown
- 2003-11-17 EP EP03811632A patent/EP1565205A4/en not_active Withdrawn
- 2003-11-17 AU AU2003297285A patent/AU2003297285A1/en not_active Abandoned
- 2003-11-17 JP JP2004570419A patent/JP2006506097A/ja active Pending
- 2003-11-17 RU RU2005118998/15A patent/RU2005118998A/ru not_active Application Discontinuation
- 2003-11-17 US US10/714,817 patent/US20040219131A1/en not_active Abandoned
- 2003-11-17 KR KR1020057008337A patent/KR20050086498A/ko not_active Withdrawn
- 2003-11-17 WO PCT/US2003/036682 patent/WO2004046365A2/en not_active Ceased
- 2003-11-17 BR BR0316324-5A patent/BR0316324A/pt not_active Application Discontinuation
- 2003-11-17 MX MXPA05005263A patent/MXPA05005263A/es not_active Application Discontinuation
- 2003-11-17 CA CA002504267A patent/CA2504267A1/en not_active Abandoned
-
2005
- 2005-04-14 IL IL168049A patent/IL168049A0/en unknown
- 2005-05-12 NO NO20052363A patent/NO20052363L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1565205A2 (en) | 2005-08-24 |
| EP1565205A4 (en) | 2006-07-05 |
| KR20050086498A (ko) | 2005-08-30 |
| JP2006506097A (ja) | 2006-02-23 |
| WO2004046365A2 (en) | 2004-06-03 |
| US20040219131A1 (en) | 2004-11-04 |
| WO2004046365A3 (en) | 2004-09-02 |
| RU2005118998A (ru) | 2006-01-27 |
| AU2003297285A1 (en) | 2004-06-15 |
| NO20052363D0 (no) | 2005-05-12 |
| MXPA05005263A (es) | 2005-07-25 |
| NO20052363L (no) | 2005-08-08 |
| IL168049A0 (en) | 2009-02-11 |
| CA2504267A1 (en) | 2004-06-03 |
| BR0316324A (pt) | 2005-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7314613B2 (en) | Interferon-alpha polypeptides and conjugates | |
| US7537755B2 (en) | Interferon-alpha polypeptides and conjugates | |
| US20040219131A1 (en) | Interferon-alpha polypeptides and conjugates | |
| US7619067B2 (en) | Evolved interferon-alpha polypeptides | |
| ZA200503782B (en) | Interferon-alpha polypeptides and conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed |